ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.691,32
0,05%
S&P 500
5.280,51
-0,50%
Dow Jones
39.148,63
-1,32%
Euro vs US Dollar
1,08154
-0,09%
Bitcoin
67.671,48
-2,07%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Neoleukin Therapeutics Inc (NLTX)

  7. Neoleukin Therapeutics Inc (NLTX) News

NLTX

Neoleukin Therapeutics (NLTX)

Neoleukin Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NLTX
DatumZeitQuelleÜberschriftSymbolFirma
10/05/202422h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NLTXNeoleukin Therapeutics Inc
10/05/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
07/05/202412h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202420h34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202420h33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NLTXNeoleukin Therapeutics Inc
26/04/202420h33Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NLTXNeoleukin Therapeutics Inc
22/04/202422h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
02/04/202421h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
18/03/202421h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
18/03/202421h04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NLTXNeoleukin Therapeutics Inc
15/03/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
15/03/202401h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
15/03/202401h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
07/03/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
05/03/202400h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
04/03/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
21/02/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
20/02/202422h16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NLTXNeoleukin Therapeutics Inc
15/02/202400h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202422h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202422h16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202421h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
14/02/202415h19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
06/02/202422h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
19/01/202401h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
19/01/202400h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
19/01/202400h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
19/01/202400h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
19/01/202400h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
19/01/202400h45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NLTX

Kürzlich von Ihnen besucht

NYSE
MRK
Merck
DBI
TDXP
Tec DAX
TG
DBK
Deutsche Bank
TG
TUI1
Tui
TG
D7G
Nel ASA
COIN
SOLUSD
Solana
DBI
SDXP
SDAX
NASDAQ
TSLA
Tesla
TG
ALV
Allianz
NYSE
DIS
Walt Disney
NYSE
XOM
Exxon Mobil
NYSE
NKE
Nike
NYSE
KO
Coca Cola
TG
BAYN
Bayer
AMEX
XLF
Financial Select Sector
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten